Carillon Tower Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
$23.2M Sell
137,629
-900
-0.6% -$134K 0.14% 214
2020
Q3
$20.5M Buy
138,529
+3,437
+3% +$532K 0.27% 137
2020
Q2
$22.2M Sell
135,092
-19,039
-12% -$2.92M 0.17% 181
2020
Q1
$21.1M Sell
154,131
-8,013
-5% -$1.1M 0.21% 170
2019
Q4
$21.3M Sell
162,144
-4,295
-3% -$498K 0.14% 243
2019
Q3
$18.6M Buy
166,439
+145,239
+685% +$16.2M 0.13% 259
2019
Q2
$2.35M Hold
21,200
0.02% 453
2019
Q1
$2.75M Buy
21,200
+3,400
+19% +$413K 0.02% 431
2018
Q4
$2.06M Buy
+17,800
New +$1.99M 0.02% 433

Other funds holding LLY

Carillon Tower Advisers's LLY Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Eli Lilly (LLY) stake by 0.65% in Q4 2020, selling an estimated $134K and leaving 137,629 shares worth $23.2M. The position accounts for 0.14% of the portfolio, ranked #214.

Carillon Tower Advisers first reported a position in LLY in Q4 2018 and has held it in 9 quarters since. 1,887 funds tracked by Wall St. Rank hold LLY as of Q4 2020.

  • Carillon Tower Advisers held 137,629 shares of Eli Lilly worth $23.2M as of Q4 2020.
  • Carillon Tower Advisers sold 900 Eli Lilly shares in Q4 2020, an estimated $134K.
  • Eli Lilly made up 0.14% of Carillon Tower Advisers's portfolio in Q4 2020, its #214 holding.
  • Carillon Tower Advisers first reported a position in Eli Lilly in Q4 2018 and has held it in 9 quarters since.
  • 1,887 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.